

RET PLC γ Phosphotyrosine Binding Domain Regulates Ca²⁺ Signaling and Neocortical Neuronal Migration

T. Kalle Lundgren^{1,2}*, Katsutoshi Nakahata¹*, Nicolas Fritz¹*, Paola Rebellato¹, Songbai Zhang¹, Per Uhlén¹*

1 Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden, **2** Department of Reconstructive Plastic Surgery, Karolinska University Hospital, Stockholm, Sweden

Abstract

The receptor tyrosine kinase RET plays an essential role during embryogenesis in regulating cell proliferation, differentiation, and migration. Upon glial cell line-derived neurotrophic factor (GDNF) stimulation, RET can trigger multiple intracellular signaling pathways that in concert activate various downstream effectors. Here we report that the RET receptor induces calcium (Ca²⁺) signaling and regulates neocortical neuronal progenitor migration through the Phospholipase-C gamma (PLC γ) binding domain Tyr1015. This signaling cascade releases Ca²⁺ from the endoplasmic reticulum through the inositol 1,4,5-trisphosphate receptor and stimulates phosphorylation of ERK1/2 and CaMKII. A point mutation at Tyr1015 on RET or small interfering RNA gene silencing of PLC γ block the GDNF-induced signaling cascade. Delivery of the RET mutation to neuronal progenitors in the embryonic ventricular zone using *in utero* electroporation reveal that Tyr1015 is necessary for GDNF-stimulated migration of neurons to the cortical plate. These findings demonstrate a novel RET mediated signaling pathway that elevates cytosolic Ca²⁺ and modulates neuronal migration in the developing neocortex through the PLC γ binding domain Tyr1015.

Citation: Lundgren TK, Nakahata K, Fritz N, Rebellato P, Zhang S, et al. (2012) RET PLC γ Phosphotyrosine Binding Domain Regulates Ca²⁺ Signaling and Neocortical Neuronal Migration. PLoS ONE 7(2): e31258. doi:10.1371/journal.pone.0031258

Editor: Branden Nelson, Seattle Children's Research Institute, United States of America

Received: May 16, 2011; **Accepted:** January 4, 2012; **Published:** February 15, 2012

Copyright: © 2012 Lundgren et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This study was supported by the Swedish Research Council (www.vr.se, Dnr 2005-6682, 2007-5977, 2009-3364, 2010-4392, DBRM), the Foundation for Strategic Research (CEDB), the Knut and Alice Wallenberg Foundation (CLICK and Research Fellow to PU), The Royal Swedish Academy of Sciences (PU), Åke Wiberg's Foundation (PU), Magnus Bergvall's Foundation (PU), Fredrik and Ingrid Thuring's Foundation (PU), the Swedish Society for Medical Research (PU and TKL), and the Uehara Memorial Foundation (KN). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: per.uhlen@ki.se

These authors contributed equally to this work.

Introduction

RET (REarranged during Transfection) was initially identified as an oncogene [1], but several additional important functions during development and disease have since been discovered [2,3,4]. The RET gene, on human chromosome 10q11.2, encodes a receptor tyrosine kinase that is activated by the glial cell line-derived neurotrophic factor (GDNF) family of ligands in conjunction with ligand-specific co-receptors of the GDNF-family receptor- α (GFR α) [5,6]. GDNF/GFR α -activation of RET results in trans-phosphorylation of tyrosine residues in its intracellular kinase domain that triggers multiple intracellular signaling pathways that in concert regulate cell proliferation, migration, differentiation, survival, neurite outgrowth, and synaptic plasticity [2]. Loss-of-function mutations in RET cause Hirschsprung's disease, a developmental disorder of the enteric nervous system [7], whereas gain-of-function mutations cause multiple endocrine neoplasia type 2a or b (MEN2a/b), a dominantly inherited cancer syndrome [8]. RET mediated signaling in the nervous system has for the most part been studied in cell lineages derived from the neural crest [9]. However, since both GDNF, GFR α 1 and RET are expressed in the embryonic neocortex [10], there is a growing interest in understanding the role of RET and its ligands in the central nervous system [11,12,13].

The intracellular domain of the RET protein has several tyrosine residues that become auto-phosphorylated upon ligand interaction and mediate activation of various downstream signaling targets, including the mitogen-activated protein kinase (MAPK) [3,14] and the calcium/calmodulin-dependent protein kinase II (CaMKII) [15]. Mutating RET tyrosine residue 1062 (Tyr1062) gives a phenotype that largely resembles RET deletion mutants [16,17]. Phosphorylated Tyr1062 tethers transduction effectors (including SHC, FRS2 and IRS1 family proteins [2]) to activate several signaling pathways including the Phosphatidylinositol 3-kinase (PI3K)/Akt and Ras/MAPK cascades [7]. A different RET tyrosine residue, Tyr1015, stimulates the phospholipase C γ (PLC γ) pathway [18]. Mice bearing Tyr1015 point mutation resulting in disrupted PLC γ activation show abnormal kidney development and death at 1 month of age [19]. While these findings have expanded our understanding of RET Tyr1015, little is known about downstream signaling pathways activated by RET-phosphorylated PLC γ . One potential signaling pathway that is modulated by PLC γ is cytosolic calcium (Ca²⁺) signaling.

The Ca²⁺ ion serves as a universal cytosolic messenger to control a diverse range of cellular processes in both disease and development [20,21]. Transporters of Ca²⁺ handle the temporal and spatial distribution of cytosolic Ca²⁺ by regulating influx and efflux from the extracellular milieu or release from the

endoplasmic reticulum (ER) stores [22,23]. Release of Ca^{2+} from ER mainly occurs through the inositol 1,4,5-trisphosphate (InsP_3) receptor (InsP_3R). The InsP_3R is activated by Ca^{2+} itself or by InsP_3 that is produced when PLC cleaves phosphatidylinositol 4,5-bisphosphate. An elevated cytosolic Ca^{2+} concentration triggers various downstream effectors such as MAPK and CaMKII, which subsequently modulate cellular processes including neuronal migration, axon and dendrite development and regeneration, and synaptic plasticity [23,24,25].

We here demonstrate that RET receptor activation by GDNF stimulates cytosolic Ca^{2+} signaling through a $\text{PLC}\gamma$ phosphotyrosine binding site at Tyr1015. This GDNF/RET/ $\text{PLC}\gamma$ / InsP_3R signaling cascade triggers release of Ca^{2+} from internal ER stores that subsequently phosphorylates p42/44 of MAPK (ERK1/2) and CaMKII. Additionally, we report that RET is present in the neocortex of the developing brain and that overexpressing a RET Tyr1015 point mutation perturbs GDNF-stimulated migration of neocortical neuronal progenitor cells.

Results

Calcium Signaling

Single-cell live Ca^{2+} imaging in HeLa cells was used to determine whether the RET receptor was involved in cytosolic Ca^{2+} signaling. Cells were transfected with green fluorescent protein (GFP)-tagged wild-type RET (RET^{WT}) 24 h prior to loading with the Ca^{2+} -sensitive dye Fura-2/AM (Figure 1A and B). The cytosolic Ca^{2+} concentration was exclusively examined in GFP positive cells. Treatment with GDNF and $\text{GFR}\alpha 1$ in RET^{WT} expressing cells resulted in a rapid cytosolic Ca^{2+} increase in 58% of the cells whereas an oscillatory Ca^{2+} response was observed in 25% of the cells (Table 1 and Figure 1C).

Equivalent GFP-tagged RET constructs, bearing point mutations at tyrosine residues at positions 1062 (RET^{1062}), 1015 (RET^{1015}) or both ($\text{RET}^{1062/1015}$), were used to identify a tyrosine residue that mediated the Ca^{2+} response (Figure 1A and Figure S1A). The RET^{1015} mutation abolished all cytosolic Ca^{2+} elevation (Table 1

Table 1. Characteristics of Ca^{2+} responses induced by GDNF in cells expressing various RET constructs.

	non-responding ^a	transient ^b	oscillation ^c	[n/M] ^d
	% (n)	% (n)	% (n)	
GDNF/ GFP $\text{GFR}\alpha 1$	99.0 (312)	0.6 (2)	0.3 (1)	[315/5]
RET^{WT}	17.0 (66)	58.1 (226)	24.9 (97)	[389/6]
RET^{1015}	99.1 (338)	0.6 (2)	0.3 (1)	[341/6]
RET^{1062}	9.2 (33)	66.0 (237)	24.8 (89)	[359/5]
$\text{RET}^{1015/1062}$	100.0 (421)	0 (0)	0 (0)	[421/5]

^aNon-responding cells have no Ca^{2+} increase exceeding 1.25 of the baseline.

^bTransient responding cells have one Ca^{2+} peak exceeding 1.25 of the baseline.

^cOscillatory responding cells have at least three Ca^{2+} peaks exceeding 1.25 of the baseline.

^d[number of cells/number of experiments].

doi:10.1371/journal.pone.0031258.t001

and Figure 1D), whereas the RET^{1062} mutation had no significant effect on the Ca^{2+} response triggered by GDNF (Table 1 and Figure 1E). Cells expressing the double point mutation $\text{RET}^{1015/1062}$ also failed to evoke a Ca^{2+} increase (Table 1 and Figure 1F). RET receptor-activation by GDNF therefore triggers cellular Ca^{2+} responses by a molecular mechanism involving Tyr1015, but not Tyr1062.

Signaling Pathway

The mechanism by which GDNF stimulated Ca^{2+} signaling was determined by using single cell Ca^{2+} recordings while blocking various known Ca^{2+} -regulators with small molecule inhibitors or small interfering RNA (siRNA). Tyr1015 is known to bind $\text{PLC}\gamma$ to the RET receptor, suggesting that PLC played a role in this signaling pathway. The effect of the PLC-inhibitor U73122 was therefore examined. GDNF failed to elevate cytosolic Ca^{2+} in




Figure 1. GDNF induces cytosolic Ca^{2+} signaling through Tyr1015 of RET. (A) Schematic representation of GFP-tagged RET constructs. (B) Constructs expressed in HeLa cells. (C–F) Representative single-cell Ca^{2+} recordings of GFP positive HeLa cells loaded with Fura-2/AM and subsequently treated with GDNF (100 ng/ml). (C) Cells expressing the RET^{WT} construct responded to GDNF with either Ca^{2+} transient (top trace) or Ca^{2+} oscillations (bottom trace). Cells expressing RET^{1015} (D) or $\text{RET}^{1015/1062}$ (F) failed to trigger a Ca^{2+} response following GDNF exposure. Cells expressing RET^{1062} (E) responded to GDNF in a similar manner as cells expressing RET^{WT} . doi:10.1371/journal.pone.0031258.g001

Table 2. Characteristics of Ca²⁺ responses triggered by GDNF in RET^{WT} cells treated with various inhibitors.

		non-responding ^a	transient ^b	oscillation ^c	[n/M] ^d
		% (n)	% (n)	% (n)	
RET ^{WT} +GDNF/GFRα1	vehicle	8.5 (11)	77.5 (100)	14.0 (18)	[129/3]
	U73122	98.6 (139)	1.4 (2)	0 (0)	[141/3]
	PLCγ-siRNA	96.9 (62)	3.1 (2)	0 (0)	[64/6]
	2-APB	54.9 (67)	36.9 (45)	8.2 (10)	[122/3]
	Ryanodine	25.0 (21)	66.7 (56)	8.3 (7)	[84/3]
	Thapsigargin	96.8 (150)	2.7 (4)	0.6 (1)	[155/3]
	Ca ²⁺ [0 mM] ^e	98.9 (176)	1.1 (2)	0 (0)	[178/3]
	Ca ²⁺ [1 mM] ^e	22.6 (26)	64.3 (74)	13.0 (15)	[115/3]

^aNon-responding cells have no Ca²⁺ increase exceeding 1.25 of the baseline.

^bTransient responding cells have one Ca²⁺ peak exceeding 1.25 of the baseline.

^cOscillatory responding cells have at least three Ca²⁺ peaks exceeding 1.25 of the baseline.

^d[number of cells/number of experiments].

^e[concentration of extracellular Ca²⁺].

doi:10.1371/journal.pone.0031258.t002

RET^{WT} expressing cells that were pre-treated with U73122 (Table 2 and Figure 2A). A siRNA against the PLCγ mRNA was used as an alternative method to ablate the PLCγ function. The PLCγ-siRNA drastically reduced PLCγ (Figure S1B) and blocked the GDNF-induced Ca²⁺ increase in cells expressing RET^{WT} (Table 2 and Figure 2B). The mock-siRNA failed to abolish the Ca²⁺ response (Figure 2C).

Two key proteins involved in Ca²⁺ release from the ER are the InsP₃R and the Ryanodine receptor (RyR). Exposing RET^{WT} expressing cells to the InsP₃R inhibitor 2-aminoethoxydiphenyl borate (2-APB) blocked the cytosolic Ca²⁺ increase triggered by GDNF (Table 2 and Figure 2D). In contrast, preincubating cells with Ryanodine, which prevents Ca²⁺ release through RyR,

produced no significant change in the Ca²⁺ response (Table 2 and Figure 2Ea). Another RyR blocker Dantrolene, also failed to inhibit the GDNF-induced Ca²⁺ response (Figure 2Eb).

Blocking the sarco/endoplasmic reticulum Ca²⁺-ATPase (SERCA) pump depletes the ER of Ca²⁺, so that cytosolic Ca²⁺ can no longer be elevated from ER Ca²⁺ stores. Pre-treatment of RET^{WT} expressing cells with the SERCA pump inhibitor Thapsigargin triggered a typical cytosolic transient Ca²⁺ increase as the ER stores depleted. Subsequent GDNF exposure failed to elevate free cytosolic Ca²⁺ (Table 2 and Figure 2F). GDNF-induced cytosolic Ca²⁺ signaling therefore appeared to come from the ER.

The contribution of extracellular Ca²⁺ was also investigated by recordings in Ca²⁺ free medium. The GDNF-induced cytosolic




Figure 2. A RET/PLCγ/InsP₃R-cascade stimulates GDNF-induced Ca²⁺ release. (A–H) Representative single-cell Ca²⁺ recordings of GFP positive RET^{WT} expressing cells loaded with Fura-2/AM and preincubated with inhibitors as indicated, following treatment with GDNF (100 ng/ml). Inhibiting PLC with U73122 (5 μM) (A) or knocking down PLCγ with siRNA (B) blocked the cytosolic Ca²⁺ response induced by GDNF. Cells transfected with the Mock-siRNA retain the Ca²⁺ response (C). Inhibiting InsP₃R with 2-APB (5 μM) abolished the Ca²⁺ response induced by GDNF (D), while inhibiting RyR with ryanodine (a, 20 μM) or dantrolene (b, 10 μM) had no effect (E). Depleting intracellular Ca²⁺ stores with the SERCA Ca²⁺-ATPase inhibitor Thapsigargin (1 μM) blocked the Ca²⁺ response (F). Zero extracellular Ca²⁺ eliminated the GDNF-induced Ca²⁺ response (G), whereas a low extracellular concentration of Ca²⁺ (1 mM) produced a normal Ca²⁺ response (H).

doi:10.1371/journal.pone.0031258.g002

Ca²⁺ response was abolished in RET^{WT} expressing cells when extracellular Ca²⁺ was removed (Table 2 and Figure 2G). This result initially suggested that the GDNF-triggered Ca²⁺ response may also derive Ca²⁺ from extracellular sources. However, the RET receptor has four extracellular cadherin-like domains that contain Ca²⁺-binding sites. Thus, extracellular Ca²⁺ ions are required for correct structural alignment of the RET receptor [26,27]. It was hence possible that the elimination of Ca²⁺ from the medium caused a structural defect in RET. Experiments were therefore repeated with lower concentrations of Ca²⁺ in the medium. A GDNF-induced Ca²⁺ response was observed with as little as 1 mM of extracellular Ca²⁺ (Table 2 and Figure 2H). Taken together, these data suggest that the GDNF-induced Ca²⁺ response comes from ER Ca²⁺ stores rather than from the extracellular milieu.

Downstream Effectors

Two proteins, MAPK and CaMKII, are typically phosphorylated when free cytosolic Ca²⁺ levels increase. Experiments were undertaken to determine if the cytosolic Ca²⁺ signal induced by the GDNF/RET/PLC γ /InsP₃R-mediated cascade of our model system could influence these two downstream effectors.

Phosphorylation of ERK1/2 was followed on Western blots. Cells transfected with RET^{WT} and exposed to GDNF for 2 to 30 min showed time-dependent ERK1/2 phosphorylation (Figure 3A). Less ERK1/2 phosphorylation was observed in the presence of BAPTA, which sequesters free cytosolic Ca²⁺ (Figure 3A). Indeed BAPTA completely abolished the elevation of cytosolic Ca²⁺ induced by GDNF (Figure S2). Parallel time course experiments showed that the mutation of Tyr1015 severely reduced or abolished the ability of RET to induce ERK1/2 phosphorylation (Figure 3B).

CaMKII was also phosphorylated when cells transfected with RET^{WT} were exposed to GDNF (Figure 3C). In contrast, phosphorylation was not observed at all in cells transfected with the RET¹⁰¹⁵ mutation (Figure 3C). The GDNF-evoked CaMKII phosphorylation was slightly attenuated by sequestering free cytosolic Ca²⁺ with BAPTA or by inhibiting PLC with U73122 (Figure 3C). The U73122 analogue, U73343, which does not inhibit PLC, did not block phosphorylation (Figure 3C). This set of experiments suggested that RET-dependent phosphorylation of ERK1/2 and CaMKII was, at least in part, induced by elevated levels of Ca²⁺.

PLC γ -siRNA was thereafter applied to further investigate PLC-mediated ERK1/2 and CaMKII phosphorylation. Knocking down PLC γ with siRNA suppressed phosphorylation of ERK1/2 and CaMKII in cells transfected with RET^{WT} and exposed to GDNF (Figure 3D).

In summary, these results indicate that GDNF/RET-induced Ca²⁺ signaling phosphorylates ERK1/2 and CaMKII by a mechanism that absolutely depends on a Tyr at amino acid 1015 of the RET receptor.

Cell Motility

Since GDNF/RET has been reported to regulate cell migration [9], experiments were performed to examine whether GDNF/RET-induced Ca²⁺ signaling influenced cell motility. A wound healing assay was used, in which HeLa cells were grown to confluence and a caliper-measured scratch was made in the adherent cell layer (Figure 4A). In the absence of GDNF, RET^{WT} transfected cells failed to move over the scratched area in the next 6–8 h (Figure 4B). However, when GDNF was included in the medium the scratch was populated by cells (Figure 4A and B). Treating the RET^{WT} transfected cells with BAPTA or U73122 significantly inhibited the observed effect (Figure 4A and B).




Figure 3. GDNF-induced Ca²⁺ signaling phosphorylates ERK1/2 and CaMKII. (A–D) Western blot of HeLa cells transfected with RET^{WT} or RET¹⁰¹⁵ treated with GDNF (100 ng/ml). GDNF triggers time dependent phosphorylation of ERK1/2 (pERK1/2) in RET^{WT} cells that is suppressed by BAPTA (10 μ M) (A). Less pERK1/2 is observed in cells transfected with RET¹⁰¹⁵ than RET^{WT} (B). GDNF-induced phosphorylation of CaMKII (pCaMKII) or pERK1/2 is suppressed when blocking PLC with U73122 (5 μ M) (C) or knocking down PLC γ with siRNA (PLC γ -siRNA) (D). Treating RET^{WT} cells with the U73122 analogue U73343 (5 μ M) had no effect on GDNF-activated pCaMKII or pERK1/2 (C). Increased Caspase-3 cleavage was not detected in cells treated with the inhibitors BAPTA or U73122 (C).

doi:10.1371/journal.pone.0031258.g003




Figure 4. GDNF-induced Ca^{2+} signaling stimulates cell motility *in vitro*. (A) Cell motility assay in HeLa cells transfected with RET^{WT} or RET¹⁰¹⁵ and treated with GDNF (100 ng/ml) for 6–8 h. (B) Cell motility was significantly higher in RET^{WT} transfected cells treated with GDNF, as compared to control cells without GDNF. Buffering cytosolic Ca^{2+} with BAPTA (10 μM) or inhibiting PLC with U73122 (5 μM) abolished the cell motility. GDNF failed to stimulate cell motility in cell transfected with RET¹⁰¹⁵. Bars represent the average number of cells in the scratch. * $P < 0.05$ versus control. doi:10.1371/journal.pone.0031258.g004

BAPTA and U73122 did not stimulate early apoptosis, as no significant level of cleaved Caspase-3 was detected by Western blot (Figure 3C). Cells transfected with the RET¹⁰¹⁵ mutant showed significantly fewer cells in the scratched area after treatment with GDNF than cells transfected with RET^{WT} (Figure 4A and B). RET¹⁰¹⁵ did not induce significant Caspase-3 cleavage (Figure 3C),

which suggested that the decreased number of cells in the scratched area was likely to be an effect of reduced cell motility caused by the Tyr1015 mutation.

To explore the biological relevance of GDNF/RET-induced Ca^{2+} signaling, we next performed experiments using an *in vivo* model of neocortical migration. Immunohistochemistry on mouse E14.5 brain coronal slices revealed a homogenous RET expression in the embryonic neocortex (Figure 5A and B). The neural stem cells of the ventricular zone and more differentiated cells in the intermediate zone (IZ) and cortical plate were all expressing RET (Figure 5B and Figure S3). Western blotting (Figure 5C) and reverse transcription-PCR (Figure 5D), in accordance with the results obtained by Ibáñez and co-workers [10], showed that neural cells of the cortex were expressing endogenous RET. Cerebellum, which is known to express high levels of RET, was used as positive control [28], whereas NIH3T3 cells was used as negative control [29]. A quantitative measure of mRNA levels using real-time PCR revealed a weaker, but significant, expression of RET in the embryonic cortex (Figure 5E). Primary cultures of cerebral cortical neurons at E14.5 loaded with Fura-2/AM responded to GDNF (100 ng/ml) with a rapid Ca^{2+} response in 8.6% ($n = 151$) of the cells. Expressing RET^{WT} in primary cortical neurons produced a rapid Ca^{2+} response in 12.9% ($n = 31$) of the cells (Figure 5F) whereas none of the cells expressing RET¹⁰¹⁵ responded to GDNF ($n = 34$). *Ex utero* electroporation was then performed to determine whether the Tyr1015 of RET played a




Figure 5. Endogenous RET is expressed in the embryonic neocortex. Immunohistochemistry of an E14.5 mouse forebrain coronal slice (A, Scale bars, 250 μm) and cortical plate (CP), intermediate zone (IZ) and ventricular zone (VZ) regions (B, Scale bars, 25 μm) for RET and TuJ1. Western blot (C), reverse transcription PCR (35 cycles) (D) and real-time PCR (E) analysis for RET in cortical tissue. Cerebellar tissue and NIH3T3 cells were used as controls. TATA-box binding protein (TBP) was the house keeping gene. (F) Representative single-cell Ca^{2+} recording of a RET^{WT} expressing primary cortical neuron loaded with Fura-2/AM and subsequently treated with GDNF (100 ng/ml). doi:10.1371/journal.pone.0031258.g005

role for neocortical neuronal migration. RET^{WT} or RET¹⁰¹⁵ constructs were injected into the lateral ventricles of E14.5 embryonic forebrains and electroporated *ex utero* (Figure 6A). Organotypic slice cultures were thereafter prepared from the electroporated embryos and beads soaked in GDNF (500 ng/ml) were placed on top of the cortical plate (CP) for 48–72 h (Figure 6A). Confocal z-stack images of electroporated regions were then recorded and GFP-positive neuronal progenitor cells in the ventricular zone (VZ) of the neocortex were analyzed for migration. RET^{WT} expressing cells showed a significant 6.3 ± 0.7 -fold ($n = 5$) increase in migration towards the GDNF-beads in the CP, as compared to control regions and vehicle (Figure 6B and C). Blocking PLC with U73122 significantly inhibited the GDNF/RET-stimulated migratory movement (1.0 ± 0.1 -fold increase, $n = 6$) of RET^{WT} expressing cells (Figure 6B). Treating slices with U73343, a U73122 analogue that does not inhibit PLC, did not inhibit the observed migration (5.0 ± 0.4 -fold increase, $n = 6$). These results indicated that PLC-dependent GDNF/RET-signaling played a role in the migratory movement of neuronal progenitor cells overexpressing RET in the VZ.

The RET¹⁰¹⁵ construct was thereafter delivered into the embryonic VZ progenitor cells to further test the influence of RET Tyr1015 on neuronal migration. GDNF-beads in the CP

failed to stimulate migration (0.3 ± 0.1 -fold increase, $n = 4$) of neocortical neuronal progenitors expressing the RET¹⁰¹⁵ construct (Figure 6B and D).

In conclusion, our results demonstrate that RET is expressed in the embryonic neocortex and that GDNF-stimulated neocortical progenitor migration in the developing brain is modulated by Tyr1015 of the RET receptor.

Discussion

In the present study we show that GDNF evokes cytosolic Ca²⁺ signaling by releasing Ca²⁺ from ER stores. The release is dependent on RET, PLC γ , and InsP₃R and modulates ERK1/2 and CaMKII phosphorylation. The signaling cascade is mediated by a single residue of RET since a point mutation of Tyr1015 fails to initiate the signaling event. Delivery of the RET Tyr1015 mutant DNA to HeLa cells or neuronal progenitors in the VZ of mouse embryos impairs GDNF-stimulated cell motility *in vitro* as well as *in vivo*.

The clinical relevance of RET was established when it was shown that germline mutations of the RET gene were responsible for two inherited human disorders, those being Hirschsprung's disease and MEN2a/b [3,8]. Hirschsprung's disease is a complex




Figure 6. RET Tyr1015 mediates GDNF-stimulated migration *in vivo*. (A) Cartoon illustrating mouse embryo electroporation and GDNF-bead stimulated migration. (B–D) Migration of cortical progenitors in organotypic brain slices from embryos electroporated with RET^{WT} (C) or RET¹⁰¹⁵ (D) treated without beads (Control) or with beads (indicated with circles) soaked in PBS (Vehicle) or GDNF (500 ng/ml) placed in the cortical plate (CP). GFP positive RET^{WT} expressing progenitors (green) stimulated with GDNF beads (B, C) show significantly enhanced migration from the ventricular zone (VZ) towards the CP, as compared to Control, Vehicle, or inhibition of PLC with U73122 (5 μM). In RET¹⁰¹⁵ expressing progenitors GDNF beads failed to stimulate migration (B, D). Scale bars, 100 μm . doi:10.1371/journal.pone.0031258.g006

developmental genetic disorder characterized by the absence of enteric ganglia in the intestinal tract, whereas MEN2a/b is a cancer syndrome that affects neuroendocrine organs. Various mutations in the RET gene have been identified and correlated with these two disorders [2]. Interestingly, the disease phenotypes of Hirschsprung's disease and MEN2a/b show partial resemblance with previously reported Ca²⁺ signaling-dependent disorders [30,31,32,33]. Thus, RET regulated Ca²⁺ signaling may be involved in Hirschsprung's disease and MEN2a/b. In the case of RET as an oncogene the results presented herein might be of clinical benefit as cytosolic Ca²⁺ signaling is implicated in general cancer growth as well as in thyroid cancers of the MEN2b type [30,34,35]. Tumor cell proliferation has recently been reported in papillary thyroid carcinoma through a signaling pathway where RET, MAPK, and CaMKII contributes [15]. However, this study is the first report of RET-induced Ca²⁺ signaling dependent on a specific phosphotyrosine and will contribute to the overall understanding of RET-regulated cell mechanisms in human diseases.

Tyr1062 of RET mediates most of the well characterized interaction with different adaptor proteins [36,37]. However, several phosphorylation sites exist and may work independently or in concert to activate certain cellular processes. For example, a synchronized activation of RET Tyr905, Tyr1015, and Tyr1062 has been detected in embryonic mouse dorsal root ganglia [36]. Phosphorylation of RET Tyr1015 activates the PLC γ pathway [18] and is important in kidney development because mutation of this residue abolishes the otherwise competent rescue of Tyr1062 mutations by Tyr1096 in the long isoform of RET [19]. Mutation of RET Tyr697, a putative protein kinase A (PKA) phosphorylation site, causes migration defects in enteric neural crest cells [38]. This and other observations [39] show a link between cyclic AMP (cAMP) and RET mediated cell signaling. cAMP levels also affect cytosolic Ca²⁺ signaling influences neuronal survival, regeneration, and growth cone remodeling [40,41,42]. Our results demonstrate that RET Tyr1015 mediates a GDNF-triggered increase in cytosolic Ca²⁺ and modulates neuronal progenitor migration in the embryonic neocortex. The demonstration of RET expression and function in the developing brain raise the possibility that the RET receptor plays an important role in the embryonic cortex.

GDNF/RET has previously been reported to modulate differentiation and migration through multiple cell signaling pathways. For example, migration of enteric nervous system progenitor cells and cortical GABAergic neurons has been linked to the pathways of Ras/ERK and PI3K/Akt [10,12,43], respectively. The GDNF-stimulated tangential migration of GABAergic neurons was dependent of GFR α 1 but not of RET [10]. Moreover, in a recent study, mice with a homozygous deletion of the kinesin superfamily protein 26A (KIF26A^{-/-}) were shown to have perturbed enteric neuronal development as a result of hypersensitivity to RET signaling [44]. Also Akt/ERK signaling played an essential role for GDNF/RET-dependent enteric neuronal development in the KIF26A^{-/-} mice. Neurite outgrowth in human neuroblastoma cells stimulated by RET was shown to be regulated through downstream activation of Ras/ERK [14]. A recent study suggests that ERK-dependent GDNF/RET-induced neurite outgrowth is suppressed by the RET-binding protein Rap1GAP [45]. In somatotrophs, the pituitary cells secreting growth hormones during infancy and puberty, activation of protein kinase C (PKC) and cAMP response element-binding (CREB) transcription factor are regulated through RET-mediated signaling pathway [46]. Mice lacking the RET receptor display early differentiation defects of the dorsal root ganglia somatosen-

sory neurons [47]. Interestingly, all the proteins Akt, CREB, ERK, PI3K, PKC, and Ras are known to be partially regulated by Ca²⁺ signaling [22]. A connection between GDNF/RET and Robo2/Slit2, yet another signaling pathway known to be regulated by Ca²⁺ signaling [48], in promoting ureteric bud outgrowth has been reported [49]. Nonetheless, how GDNF/RET triggers Slit2/Robo2 signaling is not clear but might be attributed to Ca²⁺ signaling. Such a Ca²⁺ signaling link between RET and Slit2/Robo2 could, at least in part, be involved in the GDNF-directed neuronal migration in neocortex of the developing brain.

Our results demonstrate a novel RET signaling pathway where GDNF stimulates cytosolic Ca²⁺ signaling through the PLC γ phosphotyrosine binding site Tyr1015 of RET. This GDNF/RET/PLC γ /InsP₃R signaling cascade elevates the cytosolic Ca²⁺ concentration by releasing Ca²⁺ from internal ER stores. The cytosolic Ca²⁺ response mediated through Tyr1015 of RET subsequently phosphorylates the downstream effectors ERK1/2 and CaMKII. Our data also show that RET is homogeneously expressed in the cortex of the developing brain. Mutating Tyr1015 and delivering the DNA to neuronal progenitors in the VZ of mouse embryos impairs GDNF-stimulated migration in the developing neocortex. These data further the understanding of the multifactorial RET receptor in regulating multiple signaling pathways and biological processes.

Materials and Methods

Cells, tissues and plasmids

Human cervical carcinoma HeLa cells and mouse embryonic NIH3T3 fibroblasts (obtained from the American Type Culture Collection), were grown in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum. Embryonic brain slices were obtained from wild type CD1 pregnant mice euthanized at 14.5 days postcoitum. Cerebral cortical neurons in primary culture were prepared from CD1 mouse fetuses at E15.5 as described elsewhere [24]. Experiments were approved by the Stockholm North Ethical Committee on Animal Experiments (Permit Number: N370/09). RET mutants were harbored and expressed in PJ7 Ω plasmids and subcloned into peGFP vectors (Clontech) to make fluorescent constructs, as previously described [37].

Reagents

Reagents and concentrations, unless otherwise stated, were as follows: GDNF (100 ng/ml, R&D Systems), GFR α 1/FC chimera (400 ng/ml, R&D Systems), U73122 (5 μ M, Sigma-Aldrich), U73343 (5 μ M, Sigma-Aldrich), 2-aminoethoxydiphenyl borate (2-APB, 5 μ M, Sigma-Aldrich), Ryanodine (20 μ M, Sigma-Aldrich), Dantrolene (10 μ M, Tocris), Thapsigargin (1 μ M, Sigma-Aldrich), and bis(2-aminophenoxy)ethane tetraacetic acid (BAPTA, 10 μ M, Molecular-Probes).

Cytosolic Ca²⁺ imaging

Cells were loaded with the Ca²⁺-sensitive fluorescence indicator Fura-2/AM (5 μ M, Molecular-Probes) in cell culture medium at 37°C with 5% CO₂ for 30 min. The Ca²⁺ measurements were conducted at 37°C in a heat-controlled chamber (Warner Instruments) with a cooled back-illuminated EMCCD camera Cascade II:512 (Photometrics) mounted on an inverted microscope Axiovert 100M (Carl Zeiss) equipped with a LCI Plan-Neofluar 25 \times /0.8NA water immersion lens (Carl Zeiss). Excitation at 340, 380 and 495 nm took place using a Lambda LS xenon-arc lamp (Sutter Instrument) equipped with a Lambda 10-3 filter-wheel (Sutter Instrument) and a SmartShutter (Sutter Instrument). Emission wavelengths were detected at 510 nm, and

the sampling frequency was set to 0.2 to 1 Hz. MetaFluor software (Molecular Devices) was used to control all devices and to analyze the acquired images. The experiments were performed in Krebs-Ringer's buffer containing 119.0 mM NaCl, 2.5 mM KCl, 2.5 mM CaCl₂, 1.3 mM MgCl₂, 1.0 mM NaH₂PO₄, 20.0 mM Hepes (pH 7.4), and 11.0 mM dextrose. Drugs were bath-applied.

Western blotting

Cells were lysed by sonication and protein concentrations were determined using a BCA protein assay (Pierce). Equal amounts of cellular protein were separated by sodium dodecyl sulphate gel electrophoresis, followed by wet transfer to PVDF membranes. Membranes were blocked in 5% skim milk in Tris-buffered saline solution plus 0.5% Tween-20 for 1 h before being incubated with primary antibodies (1:1000 ERK1/2, 1:1000 pERK1/2, 1:1000 pCaMKII, 1:1000 Cleaved Caspase-3, all from Cell Signaling, 1:1000 pPLC γ , 1:2000 RET H-300 from Santa Cruz or 1:200 RET AF482 from R&D Systems) overnight at 4°C and re-incubated with horseradish peroxidase-conjugated secondary antibody (1:5000–10000 from GE Healthcare) for 1 h. Immunoreactive bands were visualized using an enhanced chemiluminescence kit (GE Healthcare).

Immunohistochemistry

Mouse brain slices were cut (30–100 μ m) with a vibratome (Leica), fixed with 4% PFA overnight at 4°C and then incubated in a blocking solution (PBS, 5% Normal Goat serum, 0.1–0.3% Triton X100, 1% Bovine Serum Albumin) for 1 h at 24°C. Blocking solution was replaced by washing solution (PBS, 0.5% Normal Goat serum, 0.3% Triton X100, 1% Bovine Serum Albumin) containing the appropriate dilution of the primary antibody overnight at 4°C. Primary antibodies used were anti-RET (1/1000, R&D Systems) or anti-Tuj1 (1/400, Millipore). Alexa Fluor 488 and 555 secondary antibodies (Invitrogen) were used to reveal the primary antibodies (1/1000, 1–2 h, 24°C). TO-PRO-3 (Invitrogen) and only secondary antibody staining were used as control (Figure S3). Slices were mounted in Glycergel (Invitrogen) and observed using confocal microscopy (Carl Zeiss LSM 5 Exciter). Images were processed using the Fiji software (NIH).

Cell motility assay

Cells transfected with RET^{WT} and RET¹⁰¹⁵ were seeded in plastic culture dishes and grown to confluence. A 1.2-mm wide region devoid of cells was made in the dish using a 200- μ l plastic pipette tip held against a caliper. Cells were starved overnight and then pretreated with the Ca²⁺ inhibitors for 30 min before GDNF and GFR α 1 stimulation for 6–8 h. Quantification of cells moving into the empty region were performed by counting the number of cells within equal areas using bright-field light microscopy. Images were captured using a digital camera (Olympus C-7070) and processed in the Photoshop Lightroom software (Adobe).

siRNA knock down

Cells were transfected with 80 nM specific small interfering RNA (siRNA) against PLC (PLCG1 ON-TARGETplus SMART-pool, art nr L-003559-00-0005, Dharmacon) or non-targeting siRNA (Mock-siRNA) as a control (Stealth nontarget siRNA, GC medium composition) by using Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol. Efficiency was determined by Western Blot towards PLC γ .

Transfections and whole embryo electroporation

Transfection of HeLa cells was conducted using Lipofectamine 2000 (Invitrogen) in Opti-MEM (Invitrogen) according to the manufacturer's protocol. Electroporation of mouse embryos and organotypic brain slice culture were conducted as described previously [50,51]. Briefly, a wild type CD1 pregnant mouse was euthanized at 14.5 days postcoitum and the embryos were taken out. A glass capillary was inserted into the lateral ventricle of the embryos, and 2–4 μ l of 0.5 μ g/ μ l RET^{WT} or RET¹⁰¹⁵ plasmids with 0.01% Fast Green FCF (Sigma-Aldrich) in phosphate buffered saline (PBS) were injected (Figure 6A). After injection, the forebrain area of an embryo was held with a forceps-type electrode (BTX Harvard Apparatus) with the anode on the dorsal cortical side of the injected ventricle and five cycles of square electric pulses (50 V, 50 ms) with 950 ms intervals were delivered to the embryo using an electroporator (BTX Harvard Apparatus). Experiments were approved by the Stockholm North Ethical Committee on Animal Experiments (Permit Number: N370/09).

After electroporation, coronal slices (300 μ m) of the forebrain were obtained using a vibratome (Leica) and cultured in Neurobasal medium supplemented with B27. A maximum of three beads (Cibacron blue CGA, Sigma-Aldrich) of diameter \sim 100 μ m soaked (4–6 h, 4°C) in GDNF (500 ng/ml) or in PBS were placed in the cortical plate (CP) as described [10]. After 48–72 h, slices were fixed with PFA 4% overnight at 4°C and stained with TO-PRO-3 (Invitrogen). For each separate condition, superimposed z-stack confocal images were analyzed for number of GFP-positive progenitors per μ m³ in a spherical region with diameter twice of the GDNF-bead (Figure 6C and D). A region in a similar location of the slice, more than \sim 400 μ m away from the beads, was used to normalize the results. Experiments where beads were misplaced to other areas than the CP were discarded from the analysis.

Reverse Transcription and Real Time PCR

Total RNA was extracted from cultured cortical neurons using RNeasy kit (Qiagen). RNA quality and quantity were measured with Nanodrop 2000 (Thermo Scientific). RNA was then treated with DNaseI (Biolabs) and reverse transcription was conducted with Superscript II reverse transcriptase (Invitrogen) according to manufacturer's protocol. cDNA from NIH3T3 cells and mouse E15.5 cerebellum served as negative and positive control, respectively. Reverse transcription-PCR analysis was performed using Taq Polymerase (Invitrogen), and primers were as follows: RET forward GTACACAAACACTCCTCTCAGG, reverse CAGGCTCCTGTTGAGAATCAG, TATA-box binding protein (TBP) forward GGGGAGCTGTGATGTGAAGT, reverse CCAGGAAATAATTCTGGCTCA. The thermal cycling conditions were: 94°C for 4 min, 35 cycles of 94°C (30 s), 60°C (30 s), and 72°C (30 s) and at the end 72°C for 4 min. The PCR products were separated on 2% agarose gel and visualized under ChemiDoc XRS+ (Biorad) after staining with GelRed (Biotium). Real-time PCR was performed in triplicates using SYBR green PCR master mix according to the manufacturer's instruction (Applied Biosystems) in a 7900HT Fast real-time PCR system (Applied Biosystems). Products were analyzed with ABI 7900HT Sequence Detection System (Applied Biosystems). 2^{- Δ Ct} values were used to calculate the relative expression levels and were given as mean \pm SEM.

Data analysis

The Ca²⁺ recording data were normalized and cells were considered responsive to a treatment if the mean fluorescence was increased by at least 25% over the baseline. The data were

presented as means \pm SEM. Student's *t*-test was used and significance was accepted at $P < 0.05$.

Supporting Information

Figure S1 Western blotting of HeLa cells transfected with RET^{WT} or RET¹⁰¹⁵. (A) Cells expressing RET^{WT} or RET¹⁰¹⁵ treated with GDNF (100 ng/ml) show normal phosphorylation of RET Tyrosine residues. (B) Small interfering RNA (siRNA) against PLC γ (PLC γ -siRNA) knocked-down the PLC γ protein level in HeLa cells expressing RET^{WT}. (PDF)

Figure S2 GDNF/RET-induced Ca²⁺ signalling is inhibited by BAPTA. Representative single-cell Ca²⁺ recording of a Fura-2/AM-loaded HeLa cell transfected with RET^{WT} and treated with GDNF (100 ng/ml). Quenching intracellular Ca²⁺ with BAPTA (10 μ M) abolishes the GDNF/RET-triggered Ca²⁺ response. (PDF)

References

- Takahashi M, Ritz J, Cooper GM (1985) Activation of a novel human transforming gene, *ret*, by DNA rearrangement. *Cell* 42: 581–588.
- Arighi E, Borrello MG, Sariola H (2005) RET tyrosine kinase signaling in development and cancer. *Cytokine Growth Factor Rev* 16: 441–467.
- Runeberg-Roos P, Saarna M (2007) Neurotrophic factor receptor RET: structure, cell biology, and inherited diseases. *Ann Med* 39: 572–580.
- Santoro M, Carlomagno F, Melillo RM, Fusco A (2004) Dysfunction of the RET receptor in human cancer. *Cell Mol Life Sci* 61: 2954–2964.
- Eketjall S, Fainzilber M, Murray-Rust J, Ibanez CF (1999) Distinct structural elements in GDNF mediate binding to GFR α 1 and activation of the GFR α 1-c-RET receptor complex. *EMBO J* 18: 5901–5910.
- Leppanen VM, Bespalov MM, Runeberg-Roos P, Puurand U, Merits A, et al. (2004) The structure of GFR α 1 domain 3 reveals new insights into GDNF binding and RET activation. *EMBO J* 23: 1452–1462.
- Manie S, Santoro M, Fusco A, Billaud M (2001) The RET receptor: function in development and dysfunction in congenital malformation. *Trends Genet* 17: 580–589.
- Plaza-Menacho I, Burzynski GM, de Groot JW, Eggen BJ, Hofstra RM (2006) Current concepts in RET-related genetics, signaling and therapeutics. *Trends Genet* 22: 627–636.
- Airaksinen MS, Saarna M (2002) The GDNF family: signalling, biological functions and therapeutic value. *Nat Rev Neurosci* 3: 383–394.
- Pozas E, Ibanez CF (2005) GDNF and GFR α 1 promote differentiation and tangential migration of cortical GABAergic neurons. *Neuron* 45: 701–713.
- Mijatovic J, Airavaara M, Planken A, Auvinen P, Raasmaja A, et al. (2007) Constitutive Ret activity in knock-in multiple endocrine neoplasia type B mice induces profound elevation of brain dopamine concentration via enhanced synthesis and increases the number of TH-positive cells in the substantia nigra. *J Neurosci* 27: 4799–4809.
- Paratcha G, Ledda F (2008) GDNF and GFR α : a versatile molecular complex for developing neurons. *Trends Neurosci* 31: 384–391.
- Yu T, Scully S, Yu Y, Fox GM, Jung S, et al. (1998) Expression of GDNF family receptor components during development: implications in the mechanisms of interaction. *J Neurosci* 18: 4684–4696.
- Uchida M, Enomoto A, Fukuda T, Kurokawa K, Maeda K, et al. (2006) Dok-4 regulates GDNF-dependent neurite outgrowth through downstream activation of Rap1 and mitogen-activated protein kinase. *J Cell Sci* 119: 3067–3077.
- Rusciano MR, Salzano M, Monaco S, Sapio MR, Illario M, et al. (2010) The Ca²⁺-calmodulin-dependent kinase II is activated in papillary thyroid carcinoma (PTC) and mediates cell proliferation stimulated by RET/PTC. *Endocr Relat Cancer* 17: 113–123.
- Asai N, Murakami H, Iwashita T, Takahashi M (1996) A mutation at tyrosine 1062 in MEN2A-Ret and MEN2B-Ret impairs their transforming activity and association with shc adaptor proteins. *J Biol Chem* 271: 17644–17649.
- Jijiwa M, Fukuda T, Kawai K, Nakamura A, Kurokawa K, et al. (2004) A targeting mutation of tyrosine 1062 in Ret causes a marked decrease of enteric neurons and renal hypoplasia. *Mol Cell Biol* 24: 8026–8036.
- Borrello MG, Alberti L, Arighi E, Bongarzone I, Battistini C, et al. (1996) The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase C γ . *Mol Cell Biol* 16: 2151–2163.
- Jain S, Encinas M, Johnson EM, Jr., Milbrandt J (2006) Critical and distinct roles for key RET tyrosine docking sites in renal development. *Genes Dev* 20: 321–333.
- Berridge MJ, Bootman MD, Lipp P (1998) Calcium—a life and death signal. *Nature* 395: 645–648.
- Clapham DE (2007) Calcium signaling. *Cell* 131: 1047–1058.
- Berridge MJ, Bootman MD, Roderick HL (2003) Calcium signalling: dynamics, homeostasis and remodelling. *Nat Rev Mol Cell Biol* 4: 517–529.
- Uhlen P, Fritz N (2010) Biochemistry of calcium oscillations. *Biochem Biophys Res Commun* 396: 28–32.
- Desfrere L, Karlsson M, Hiyoshi H, Malmersjo S, Nanou E, et al. (2009) Na,K-ATPase signal transduction triggers CREB activation and dendritic growth. *Proc Natl Acad Sci U S A* 106: 2212–2217.
- Zheng JQ, Poo MM (2007) Calcium signaling in neuronal motility. *Annu Rev Cell Dev Biol* 23: 375–404.
- Anders J, Kjar S, Ibanez CF (2001) Molecular modeling of the extracellular domain of the RET receptor tyrosine kinase reveals multiple cadherin-like domains and a calcium-binding site. *J Biol Chem* 276: 35808–35817.
- Kjaer S, Ibanez CF (2003) Identification of a surface for binding to the GDNF-GFR α 1 complex in the first cadherin-like domain of RET. *J Biol Chem* 278: 47898–47904.
- Golden JP, DeMaro JA, Osborne PA, Milbrandt J, Johnson EM, Jr. (1999) Expression of neurturin, GDNF, and GDNF family-receptor mRNA in the developing and mature mouse. *Exp Neurol* 158: 504–528.
- Schmutzler BS, Roy S, Pittman SK, Meadows RM, Hingtgen CM (2011) Ret-dependent and Ret-independent mechanisms of GII-induced sensitization. *Mol Pain* 7: 22.
- Roderick HL, Cook SJ (2008) Ca²⁺ signalling checkpoints in cancer: remodelling Ca²⁺ for cancer cell proliferation and survival. *Nat Rev Cancer* 8: 361–375.
- Berridge MJ, Lipp P, Bootman MD (2000) The versatility and universality of calcium signalling. *Nat Rev Mol Cell Biol* 1: 11–21.
- Cook SJ, Lockyer PJ (2006) Recent advances in Ca(2+)-dependent Ras regulation and cell proliferation. *Cell Calcium* 39: 101–112.
- Monteith GR, McAndrew D, Faddy HM, Roberts-Thomson SJ (2007) Calcium and cancer: targeting Ca²⁺ transport. *Nat Rev Cancer* 7: 519–530.
- Watanabe T, Ichihara M, Hashimoto M, Shimono K, Shimoyama Y, et al. (2002) Characterization of gene expression induced by RET with MEN2A or MEN2B mutation. *Am J Pathol* 161: 249–256.
- Richardson DS, Gujral TS, Peng S, Asa SL, Mulligan LM (2009) Transcript level modulates the inherent oncogenicity of RET/PTC oncoproteins. *Cancer Res* 69: 4861–4869.
- Couplier M, Anders J, Ibanez CF (2002) Coordinated activation of autophosphorylation sites in the RET receptor tyrosine kinase: importance of tyrosine 1062 for GDNF mediated neuronal differentiation and survival. *J Biol Chem* 277: 1991–1999.
- Lundgren TK, Stenqvist A, Scott RP, Pawson T, Ernfors P (2008) Cell migration by a FRS2-adaptor dependent membrane relocation of ret receptors. *J Cell Biochem* 104: 879–894.
- Asai N, Fukuda T, Wu Z, Enomoto A, Pachnis V, et al. (2006) Targeted mutation of serine 697 in the Ret tyrosine kinase causes migration defect of enteric neural crest cells. *Development* 133: 4507–4516.
- Fukuda T, Kiuchi K, Takahashi M (2002) Novel mechanism of regulation of Rac activity and lamellipodia formation by RET tyrosine kinase. *J Biol Chem* 277: 19114–19121.
- Seino S, Shibasaki T (2005) PKA-dependent and PKA-independent pathways for cAMP-regulated exocytosis. *Physiol Rev* 85: 1303–1342.
- Borodinsky LN, Spitzer NC (2006) Second messenger pas de deux: the coordinated dance between calcium and cAMP. *Sci STKE* 2006: pe22.

42. Malmersjo S, Liste I, Dyachok O, Tengholm A, Arenas E, et al. (2010) Ca²⁺ and cAMP signaling in human embryonic stem cell-derived dopamine neurons. *Stem Cells Dev* 19: 1355–1364.
43. Natarajan D, Marcos-Gutierrez C, Pachnis V, de Graaff E (2002) Requirement of signalling by receptor tyrosine kinase RET for the directed migration of enteric nervous system progenitor cells during mammalian embryogenesis. *Development* 129: 5151–5160.
44. Zhou R, Niwa S, Homma N, Takei Y, Hirokawa N (2009) KIF26A is an unconventional kinesin and regulates GDNF-Ret signaling in enteric neuronal development. *Cell* 139: 802–813.
45. Jiao L, Zhang Y, Hu C, Wang YG, Huang A, et al. (2010) Rap1GAP interacts with RET and suppresses GDNF-induced neurite outgrowth. *Cell Res* 21: 327–337.
46. Canibano C, Rodriguez NL, Saez C, Tovar S, Garcia-Lavandeira M, et al. (2007) The dependence receptor Ret induces apoptosis in somatotrophs through a Pit-1/p53 pathway, preventing tumor growth. *EMBO J* 26: 2015–2028.
47. Bourane S, Garces A, Venteo S, Pattyn A, Hubert T, et al. (2009) Low-threshold mechanoreceptor subtypes selectively express MafA and are specified by Ret signaling. *Neuron* 64: 857–870.
48. Guan CB, Xu HT, Jin M, Yuan XB, Poo MM (2007) Long-range Ca²⁺ signaling from growth cone to soma mediates reversal of neuronal migration induced by slit-2. *Cell* 129: 385–395.
49. Dressler GR (2006) The cellular basis of kidney development. *Annu Rev Cell Dev Biol* 22: 509–529.
50. Daza RAM, Englund C, Hevner RF (2007) Organotypic Slice Culture of Embryonic Brain Tissue. *Cold Spring Harb Protoc* 2007: pdb.prot4914.
51. Saito T (2006) In vivo electroporation in the embryonic mouse central nervous system. *Nat Protoc* 1: 1552–1558.